2026 Q2 - tulosraportti
82 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 min sittenGot 11.52, how long do you think one has to sit in the boat?I think a lot of positive things can happen that can provide a good share price movement in the next 6 months. 🤩
- ·39 min sittenExciting to see what will be presented on the Webcast💰 Could be an interesting week.
- ·7 t sitten · MuokattuInteresting post from Victor Levitsky about the challenges with ssDNA, including inflammation and efficient gene expression. As I understand him, he sees a potential for circVec to make such DNA systems more efficient and help solve some of the limitations. It remains to be seen, of course, what the ongoing trials will show. If circVec proves to provide significant benefits across different DNA systems, let us hope Circios' patent protection is strong enough to secure the company a share of the value being created. https://www.linkedin.com/posts/victor-levitsky-742b6310_whetherssdnacan-deliver-on-its-promise-share-7529975196364009472-kdZ5/
- ·1 päivä sitten · MuokattuThe response from AI about the webcast on Friday 27.11 I am uploading at least this week☺️ New research results: The company has new data showing that the technology works in living organisms, not just in cell cultures. Broader application area: The technology can potentially be used together with newer delivery systems for gene therapy. Solid Biosciences: They will provide more information about the collaboration with this biotech company. Business development: There may come interesting information about commercial opportunities and partnership collaborations. Is this share price driving? Potentially yes. The most interesting part is that Circio is already signaling new data demonstrating «in vivo proof-of-concept». This means they have achieved a form of experimental confirmation that the technology works in living organisms. However, this is not the same as documented effect in humans, and the announcement does not confirm any new licensing agreement or revenues. I interpret this as a positive research-related stock exchange announcement. Friday November 27 can be an important day for Circio shareholders, depending on how strong the new results are and what management tells about theI buy and sell a bit pretty much every day. If we drop into the eighties I will load up well, and possibly hold longer than usual. I quickly get scolded when I admit to day trading, but that is how I make my money. Circio is one of the companies I follow most closely, and consider myself long-term, but rarely sit with over 20k shares overnight. I keep those in case there should be a poc, licensing agreement or acquisition. Wiklund is a fantastic salesman, who has managed an enormous feat in raising money, but if they do not manage proof of concept within a reasonable time, I think interest will wane. Then the stock drops, and with less volume, the easier it becomes to influence the share price. Citadel, Qube, the major American banks... they know how to exploit this, and drive down the share price, to hoard cheap shares. So I follow them. I have faith in circvec, and consider Circio well derisked, but do not load up until poc is presented. For the sake of clarity, it is probably fine to mention that my trades on Nordnet do not really reflect my investments. I have other preferred trading channels. But Nordnet is more entertaining!
- ·1 päivä sitten · Muokattu
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
82 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 min sittenGot 11.52, how long do you think one has to sit in the boat?I think a lot of positive things can happen that can provide a good share price movement in the next 6 months. 🤩
- ·39 min sittenExciting to see what will be presented on the Webcast💰 Could be an interesting week.
- ·7 t sitten · MuokattuInteresting post from Victor Levitsky about the challenges with ssDNA, including inflammation and efficient gene expression. As I understand him, he sees a potential for circVec to make such DNA systems more efficient and help solve some of the limitations. It remains to be seen, of course, what the ongoing trials will show. If circVec proves to provide significant benefits across different DNA systems, let us hope Circios' patent protection is strong enough to secure the company a share of the value being created. https://www.linkedin.com/posts/victor-levitsky-742b6310_whetherssdnacan-deliver-on-its-promise-share-7529975196364009472-kdZ5/
- ·1 päivä sitten · MuokattuThe response from AI about the webcast on Friday 27.11 I am uploading at least this week☺️ New research results: The company has new data showing that the technology works in living organisms, not just in cell cultures. Broader application area: The technology can potentially be used together with newer delivery systems for gene therapy. Solid Biosciences: They will provide more information about the collaboration with this biotech company. Business development: There may come interesting information about commercial opportunities and partnership collaborations. Is this share price driving? Potentially yes. The most interesting part is that Circio is already signaling new data demonstrating «in vivo proof-of-concept». This means they have achieved a form of experimental confirmation that the technology works in living organisms. However, this is not the same as documented effect in humans, and the announcement does not confirm any new licensing agreement or revenues. I interpret this as a positive research-related stock exchange announcement. Friday November 27 can be an important day for Circio shareholders, depending on how strong the new results are and what management tells about theI buy and sell a bit pretty much every day. If we drop into the eighties I will load up well, and possibly hold longer than usual. I quickly get scolded when I admit to day trading, but that is how I make my money. Circio is one of the companies I follow most closely, and consider myself long-term, but rarely sit with over 20k shares overnight. I keep those in case there should be a poc, licensing agreement or acquisition. Wiklund is a fantastic salesman, who has managed an enormous feat in raising money, but if they do not manage proof of concept within a reasonable time, I think interest will wane. Then the stock drops, and with less volume, the easier it becomes to influence the share price. Citadel, Qube, the major American banks... they know how to exploit this, and drive down the share price, to hoard cheap shares. So I follow them. I have faith in circvec, and consider Circio well derisked, but do not load up until poc is presented. For the sake of clarity, it is probably fine to mention that my trades on Nordnet do not really reflect my investments. I have other preferred trading channels. But Nordnet is more entertaining!
- ·1 päivä sitten · Muokattu
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
82 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 min sittenGot 11.52, how long do you think one has to sit in the boat?I think a lot of positive things can happen that can provide a good share price movement in the next 6 months. 🤩
- ·39 min sittenExciting to see what will be presented on the Webcast💰 Could be an interesting week.
- ·7 t sitten · MuokattuInteresting post from Victor Levitsky about the challenges with ssDNA, including inflammation and efficient gene expression. As I understand him, he sees a potential for circVec to make such DNA systems more efficient and help solve some of the limitations. It remains to be seen, of course, what the ongoing trials will show. If circVec proves to provide significant benefits across different DNA systems, let us hope Circios' patent protection is strong enough to secure the company a share of the value being created. https://www.linkedin.com/posts/victor-levitsky-742b6310_whetherssdnacan-deliver-on-its-promise-share-7529975196364009472-kdZ5/
- ·1 päivä sitten · MuokattuThe response from AI about the webcast on Friday 27.11 I am uploading at least this week☺️ New research results: The company has new data showing that the technology works in living organisms, not just in cell cultures. Broader application area: The technology can potentially be used together with newer delivery systems for gene therapy. Solid Biosciences: They will provide more information about the collaboration with this biotech company. Business development: There may come interesting information about commercial opportunities and partnership collaborations. Is this share price driving? Potentially yes. The most interesting part is that Circio is already signaling new data demonstrating «in vivo proof-of-concept». This means they have achieved a form of experimental confirmation that the technology works in living organisms. However, this is not the same as documented effect in humans, and the announcement does not confirm any new licensing agreement or revenues. I interpret this as a positive research-related stock exchange announcement. Friday November 27 can be an important day for Circio shareholders, depending on how strong the new results are and what management tells about theI buy and sell a bit pretty much every day. If we drop into the eighties I will load up well, and possibly hold longer than usual. I quickly get scolded when I admit to day trading, but that is how I make my money. Circio is one of the companies I follow most closely, and consider myself long-term, but rarely sit with over 20k shares overnight. I keep those in case there should be a poc, licensing agreement or acquisition. Wiklund is a fantastic salesman, who has managed an enormous feat in raising money, but if they do not manage proof of concept within a reasonable time, I think interest will wane. Then the stock drops, and with less volume, the easier it becomes to influence the share price. Citadel, Qube, the major American banks... they know how to exploit this, and drive down the share price, to hoard cheap shares. So I follow them. I have faith in circvec, and consider Circio well derisked, but do not load up until poc is presented. For the sake of clarity, it is probably fine to mention that my trades on Nordnet do not really reflect my investments. I have other preferred trading channels. But Nordnet is more entertaining!
- ·1 päivä sitten · Muokattu
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt






